April 27, 2024 Alphabet and Microsoft’s AI Investments Yield Strong Returns
April 26, 2024 Top 10 High Dividend Yield Stocks
Tesla Q1: Model 2 Could Be Their Model T
Tesla Is An AI Company That The Market Won’t Reward For Now
Amazon: The Margin Train Is Gaining Speed
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
April 12, 2024 Improve Your Financial Status: A How-To Guide
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
Teva (TEVA) Stock Forecast for 2024–2028. Sell or Buy?
Updated: April 26, 2024 (08:32)
Sector: HealthcareThe share price of Teva Pharmaceutical Industries Lim. (TEVA) (TEVA) now
50/200 Day Moving Average: $13.47 / $10.72
This figure corresponds to the Average Price over the previous 50/200 days. For Teva stocks, the 50-day moving average is the resistance level today.
For Teva stocks, the 200-day moving average is the support level today.
Are you interested in Teva Pharmaceutical Industries Lim. (TEVA) stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Teva stock price in 2024, 2025, 2026, 2027, 2028. How much will one Teva share be worth in 2024 - 2028?
When should I take profit in Teva stock? When should I record a loss on Teva stock? What are analysts' forecasts for Teva stock? What is the future of Teva stock? We forecast Teva stock performance using neural networks based on historical data on Teva stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
Teva stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2024, 2025, 2026, 2027 and 2028) The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Teva shares. This happens once a day.
Historical and forecast chart of Teva stock
The chart below shows the historical price of Teva stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Teva stock price can be found in the table below.
Long-term forecasts by years.
Unlocking Teva's Stock Future: A Guide to Predicting TEVA's Market Movement
Investors and stock analysts alike are keenly observing Teva Pharmaceutical Industries, as a blend of pivotal factors could significantly sway TEVA stock forecasts. Notably, the execution of a strategic turnaround plan under new leadership is at the forefront, aimed at propelling the company into a story of growth and profitability. This plan is critical for driving sustainable growth and diversification, potentially making TEVA stock a compelling buy for investors tuned into the pharmaceutical sector's dynamic landscape.
Key Indicators for TEVA's Stock Trajectory
Delving deeper, several aspects are positioned to be game-changers for predicting TEVA's stock price movements accurately:
- Financial Performance: TEVA's journey towards bolstering its financial health, marked by rising gross and operating margins alongside positive revenue growth, is essential. Analysts contemplating the TEVA stock price target will closely monitor these indicators for signs of enduring profitability.
- Debt Reduction Efforts: With an emphasis on solid free cash flow and dedicated deleveraging, TEVA seeks to diminish its debt overhang. A decline in debt levels could significantly enhance TEVA's stock price prediction, signaling stability and financial discipline.
- Reputation and Ethical Practices: Overcoming past controversies through stringent ethical standards could rejuvenate TEVA's public image. For those debating whether TEVA stock is a good buy, the company's commitment to rectifying previous missteps could be a determinant factor.
By synthesizing these elements, analysts can craft informed TEVA stock forecasts, distinguishing TEVA as either an attractive investment or a sell. Given the TEVA name's stock forecast intricacies, investors are encouraged to weigh these decisive factors carefully, potentially unlocking lucrative opportunities in a volatile market landscape.
Review the original AnalysisUnlocking the Potential: How TEVA's Latest Moves Can Surge Stock Prices
The pharmaceutical sector is always ripe with developments that promise to shift the landscape, and TEVA Pharmaceuticals is at the forefront with exciting news that could significantly influence its stock prices. Analysts closely watching TEVA have identified pivotal events and factors that are likely to shape the company's financial trajectory in the near future.
Key Drivers of TEVA's Stock Performance
Firstly, the FDA approval of Simlandi, a biosimilar to Humira, stands out as a game-changer. This development not only opens up new market opportunities for TEVA but also enhances its revenue prospects due to Simlandi's "interchangeable" status, making it a preferred choice for many. Secondly, TEVA's financial health, evidenced by its Q4 earnings report, showcases significant growth and an optimistic 2024 outlook. This underpins the potential for positive stock price movement. Lastly, TEVA's commitment to reducing its leverage and debt presents a stable foundation, reducing risk and potentially making the stock more attractive to investors.
To make the most accurate predictions, analysts must weigh these factors comprehensively. The FDA approval of Simlandi could be seen as the most influential due to its immediate impact on market share and revenue. However, financial performance and leverage reduction are crucial for long-term stability and growth. By analyzing these dimensions collectively, analysts can develop a nuanced understanding of TEVA's stock potential, making informed predictions that leverage recent successes for future gains.
- FDA approval of Simlandi
- Financial performance and outlook
- Leverage and debt reduction
As TEVA strides forward, these factors together paint a promising picture for its stock rates, suggesting a bullish outlook for investors keeping an eye on this pharmaceutical giant.
Review the original AnalysisUnlocking TEVA’s Financial Fortunes: A Close Look at Stock Predictions
For investors eyeing TEVA Pharmaceuticals, accurately forecasting the stock's trajectory hinges on scrutinizing a set of pivotal factors. In the dynamic world of pharmaceuticals, certain events and catalysts are more influential in swaying TEVA's stock rates than others. Let's dive into these crucial elements and see how they pave the way for sharper, more informed predictions about TEVA's financial future.
Key Influencers on TEVA's Stock Horizon
High on the forecasters' list is TEVA’s promising revenue growth, buoyed by standout drugs like Austedo and Ajovy. Their impressive sales surge in 2023 stands as a beacon of TEVA’s potential turnaround. Analysts wielding this information can sketch brighter stock price projections, banking on continued revenue uplifts from these leading drugs.
However, it's not all sunny skies. The cloud of a hefty debt load and towering interest payments looms large. But here’s the silver lining: TEVA's proactive steps toward debt reduction and refinancing could soon dissipate this cloud, hinting at an upswing in stock valuations for the eagle-eyed analyst.
Biosimilars represent another frontier, with TEVA’s pipeline of candidates for heavyweight drugs like Humira and Stelara offering a clear runway for growth. Approval and market entry of these biosimilars could deliver a potent boost to TEVA’s market share and revenue. Analysts incorporating this potential into their models might see their stock price forecasts for TEVA gaining robustness and accuracy.
In essence, an intricate blend of revenue growth prospects, strategic debt management, and the promising horizon of biosimilars builds the tripod supporting TEVA's stock price forecasts. Analysts piecing together this puzzle can navigate the contours of TEVA's future with greater precision, offering investors a clearer glimpse into the company’s prospects.
Review the original AnalysisTeva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets and distributes generics, specialty drugs and biopharmaceutical products in North America, Europe and internationally. The company offers sterile products, hormones, high potency drugs and cytotoxic agents in a variety of dosage forms, including tablets, capsules, injections, inhalers, liquids, ointments and creams. It also develops, manufactures and markets active pharmaceutical ingredients. In addition, the company provides specialized medicines for use in the central nervous system and respiratory indications. In addition, its products in the central nervous system and pain areas include Copaxone for the treatment of relapsing forms of MS; ADZHOVIY for the prophylactic treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease. In addition, the company’s products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Braltus, Cinqair / Cinqaero and AirDuo RespiClick / ArmonAir RespiClick / AirDuo Digihaler for asthma and chronic obstructive pulmonary disease, as well as Bendeka products , Trisenox, Lonquex and Tevagrastim / Ratiograstim in the cancer market. She has cooperation agreements with Otsuka Pharmaceutical Co. LTD. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petah Tikva, Israel.
Teva daily forecast for a month
Date | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Apr 28 | 14.32 | 13.97 | 14.94 | 6.95 |
Apr 29 | 14.06 | 13.44 | 14.41 | 7.22 |
Apr 30 | 13.49 | 13.30 | 13.99 | 5.17 |
May 01 | 13.18 | 12.60 | 13.45 | 6.71 |
May 02 | 13.80 | 13.20 | 13.99 | 6.02 |
May 03 | 14.24 | 14.05 | 14.84 | 5.66 |
May 04 | 13.93 | 13.47 | 14.54 | 8.00 |
May 05 | 14.09 | 13.61 | 14.30 | 5.03 |
May 06 | 14.50 | 14.14 | 14.82 | 4.80 |
May 07 | 14.13 | 13.46 | 14.54 | 8.07 |
May 08 | 14.34 | 14.04 | 14.83 | 5.57 |
May 09 | 14.30 | 13.66 | 14.53 | 6.35 |
May 10 | 14.10 | 13.54 | 14.30 | 5.62 |
May 11 | 14.13 | 13.54 | 14.67 | 8.39 |
May 12 | 13.76 | 13.12 | 13.95 | 6.29 |
May 13 | 14.54 | 14.33 | 15.01 | 4.75 |
May 14 | 14.81 | 14.20 | 15.10 | 6.32 |
May 15 | 15.68 | 15.35 | 15.98 | 4.04 |
May 16 | 16.01 | 15.62 | 16.53 | 5.84 |
May 17 | 15.30 | 15.04 | 15.88 | 5.62 |
May 18 | 14.96 | 14.39 | 15.32 | 6.49 |
May 19 | 15.29 | 14.98 | 15.83 | 5.63 |
May 20 | 15.83 | 15.29 | 16.14 | 5.59 |
May 21 | 16.28 | 15.82 | 16.94 | 7.04 |
May 22 | 16.97 | 16.68 | 17.25 | 3.42 |
May 23 | 17.09 | 16.66 | 17.81 | 6.89 |
May 24 | 17.30 | 16.58 | 18.03 | 8.77 |
May 25 | 16.68 | 15.99 | 17.14 | 7.20 |
May 26 | 15.79 | 15.16 | 16.22 | 6.93 |
May 27 | 14.98 | 14.41 | 15.27 | 5.99 |
Teva Daily Price Targets
Teva Stock Forecast 04-28-2024.
Forecast target price for 04-28-2024: $14.32.
Positive dynamics for Teva shares will prevail with possible volatility of 6.499%.
Pessimistic target level: 13.97
Optimistic target level: 14.94
Teva Stock Forecast 04-29-2024.
Forecast target price for 04-29-2024: $14.06.
Negative dynamics for Teva shares will prevail with possible volatility of 6.734%.
Pessimistic target level: 13.44
Optimistic target level: 14.41
Teva Stock Forecast 04-30-2024.
Forecast target price for 04-30-2024: $13.49.
Negative dynamics for Teva shares will prevail with possible volatility of 4.917%.
Pessimistic target level: 13.30
Optimistic target level: 13.99
Teva Stock Forecast 05-01-2024.
Forecast target price for 05-01-2024: $13.18.
Negative dynamics for Teva shares will prevail with possible volatility of 6.291%.
Pessimistic target level: 12.60
Optimistic target level: 13.45
Teva Stock Forecast 05-02-2024.
Forecast target price for 05-02-2024: $13.80.
Positive dynamics for Teva shares will prevail with possible volatility of 5.678%.
Pessimistic target level: 13.20
Optimistic target level: 13.99
Teva Stock Forecast 05-03-2024.
Forecast target price for 05-03-2024: $14.24.
Positive dynamics for Teva shares will prevail with possible volatility of 5.355%.
Pessimistic target level: 14.05
Optimistic target level: 14.84
TEVA (TEVA) Monthly Stock Prediction for 2024
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
May. | 12.72 | 11.86 | 13.72 | 13.50 |
Jun. | 12.92 | 11.58 | 13.75 | 15.79 |
Jul. | 13.44 | 12.77 | 15.14 | 15.62 |
Aug. | 11.87 | 11.45 | 12.74 | 10.13 |
Sep. | 10.10 | 9.65 | 10.78 | 10.49 |
Oct. | 11.19 | 10.40 | 11.71 | 11.16 |
Nov. | 11.26 | 9.96 | 12.27 | 18.80 |
Dec. | 10.50 | 9.78 | 11.73 | 16.62 |
Teva forecast for this year
Teva Stock Prediction for May 2024
An downtrend is forecast for this month with an optimal target price of $12.7186. Pessimistic: $11.86. Optimistic: $13.72
Teva Stock Prediction for Jun 2024
An uptrend is forecast for this month with an optimal target price of $12.9221. Pessimistic: $11.58. Optimistic: $13.75
Teva Stock Prediction for Jul 2024
An uptrend is forecast for this month with an optimal target price of $13.439. Pessimistic: $12.77. Optimistic: $15.14
Teva Stock Prediction for Aug 2024
An downtrend is forecast for this month with an optimal target price of $11.8693. Pessimistic: $11.45. Optimistic: $12.74
Teva Stock Prediction for Sep 2024
An downtrend is forecast for this month with an optimal target price of $10.1031. Pessimistic: $9.65. Optimistic: $10.78
Teva Stock Prediction for Oct 2024
An uptrend is forecast for this month with an optimal target price of $11.1862. Pessimistic: $10.40. Optimistic: $11.71
Teva Stock Prediction for Nov 2024
An uptrend is forecast for this month with an optimal target price of $11.2578. Pessimistic: $9.96. Optimistic: $12.27
Teva Stock Prediction for Dec 2024
An downtrend is forecast for this month with an optimal target price of $10.5013. Pessimistic: $9.78. Optimistic: $11.73
Teva (TEVA) Monthly Stock Prediction for 2025
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 10.90 | 9.86 | 11.71 | 15.80 |
Feb | 10.05 | 9.44 | 10.56 | 10.65 |
Mar | 9.95 | 9.05 | 10.69 | 15.35 |
Apr | 10.54 | 9.73 | 11.59 | 16.01 |
May | 11.76 | 10.67 | 12.43 | 14.22 |
Jun | 13.60 | 11.86 | 14.51 | 18.29 |
Jul | 13.10 | 11.55 | 14.53 | 20.49 |
Aug | 12.93 | 11.28 | 13.37 | 15.63 |
Sep | 13.16 | 12.38 | 13.96 | 11.31 |
Oct | 14.59 | 13.77 | 15.43 | 10.74 |
Nov | 15.53 | 14.90 | 16.62 | 10.31 |
Dec | 13.56 | 12.24 | 14.73 | 16.94 |
Teva (TEVA) Monthly Stock Prediction for 2026
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 12.15 | 11.22 | 13.51 | 16.98 |
Feb | 11.74 | 11.07 | 13.21 | 16.22 |
Mar | 11.22 | 10.50 | 12.56 | 16.43 |
Apr | 12.71 | 12.20 | 13.40 | 8.95 |
May | 13.62 | 12.93 | 14.93 | 13.43 |
Jun | 15.24 | 13.53 | 17.04 | 20.60 |
Jul | 14.28 | 13.14 | 16.09 | 18.32 |
Aug | 13.48 | 12.82 | 14.00 | 8.47 |
Sep | 11.48 | 10.95 | 11.97 | 8.59 |
Oct | 10.08 | 9.00 | 11.07 | 18.66 |
Nov | 9.84 | 9.08 | 10.71 | 15.15 |
Dec | 10.20 | 9.42 | 11.31 | 16.74 |
Teva (TEVA) Monthly Stock Prediction for 2027
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 10.61 | 10.19 | 11.46 | 11.11 |
Feb | 10.78 | 9.81 | 11.14 | 11.92 |
Mar | 11.42 | 10.23 | 11.91 | 14.11 |
Apr | 12.79 | 12.22 | 13.94 | 12.33 |
May | 11.89 | 10.67 | 12.63 | 15.51 |
Jun | 11.32 | 10.65 | 11.81 | 9.82 |
Jul | 11.99 | 10.80 | 13.22 | 18.29 |
Aug | 12.89 | 11.90 | 13.80 | 13.75 |
Sep | 13.01 | 11.74 | 14.47 | 18.85 |
Oct | 13.16 | 12.32 | 13.73 | 10.28 |
Nov | 13.58 | 12.52 | 14.95 | 16.28 |
Dec | 13.28 | 12.15 | 13.87 | 12.40 |
Teva (TEVA) Monthly Stock Prediction for 2028
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 12.28 | 11.51 | 12.67 | 9.15 |
Feb | 13.42 | 12.88 | 14.25 | 9.64 |
Mar | 14.83 | 13.77 | 16.69 | 17.50 |
Apr | 16.35 | 14.50 | 16.98 | 14.64 |
May | 16.35 | 14.29 | 18.24 | 21.66 |
Jun | 18.55 | 16.59 | 19.41 | 14.53 |
Jul | 20.03 | 19.23 | 22.28 | 13.67 |
Aug | 16.96 | 14.98 | 17.74 | 15.60 |
Sep | 18.12 | 16.50 | 20.21 | 18.36 |
Oct | 18.15 | 17.46 | 19.34 | 9.76 |
Nov | 18.04 | 15.87 | 18.70 | 15.12 |
Dec | 18.84 | 16.89 | 20.11 | 16.04 |
Teva information and performance
5 BAZEL ST, P O B 3190, PETACH TIKVA, IL
Market capitalization of the Teva Pharmaceutical Industries Lim. (TEVA) is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of TEVA shares in the company outstanding by the market price of one share.
EBITDA of Teva is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
Teva (TEVA) stock dividend
Teva last paid dividends on 11/27/2017. The next scheduled payment will be on 12/12/2017. The amount of dividends is $None per share. If the date of the next dividend payment has not been updated, it means that the issuer has not yet announced the exact payment. As soon as information becomes available, we will immediately update the data. Bookmark our portal to stay updated.
Last Split Date: 01/01/1970
Splitting of shares is an increase in the number of securities of the issuing company circulating on the market due to a decrease in their value at constant capitalization.
For example, a 5: 1 ratio means that the value of one share will decrease 5 times, the total amount will increase 5 times. It is important to understand that this procedure does not change the capitalization of the company, as well as the total value of assets held in private hands.
Related stocks from Healthcare sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.